Predictive role of genetic variants in neoadjuvant chemotherapy of breast cancer

  • سال انتشار: 1396
  • محل انتشار: دومین کنگره بین المللی پزشکی شخصی
  • کد COI اختصاصی: IPMCMED02_001
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 532
دانلود فایل این مقاله

نویسندگان

H Naghash

Karaj Branch, Islamic Azad University,Karaj,Iran,Cancer Pharmacogenetics Research Group (CPGRG), Iran University of Medical Sciences, Tehran, Iran

N Ansarinejad

Iran University of Medical Sciences,Tehran,Iran,Cancer Pharmacogenetics Research Group (CPGRG), Iran University of Medical Sciences, Tehran, Iran

B Abbasi

National Institute of Genetic Engineering and Biotechnology (NIGEB),Tehran,Iran- Cancer Pharmacogenetics Research Group (CPGRG), Iran University of Medical Sciences, Tehran, Iran

T Ramim

Cancer Pharmacogenetics Research Group (CPGRG), Iran University of Medical Sciences, Tehran, Iran

چکیده

Variation in the human genome is a most important cause of variable response to drugs. Different patients respond in different ways to the same medication. There are many inter-individual differences in drug response owing to the sequence variants of genes that encode drug-metabolizing enzymes, drug transporters, or drug targets. Many studies have shown that genetic factors greatly contribute to influence the variability in drug effects. Current advances in the biology of cancer and emergence of high-throughput sequencing for genome analysis are expected to provide new approaches for optimizing treatment and lead the future direction for personalized medicine. Chemotherapy is an impor tant adjuvant systemic therapeutic approach for the successful treatment of breast cancer and, during early stage breast cancer, has been demonstrated to improve survival rate. Most of the drug-metabolizing enzymes and transporters have a broad range of genetic polymorphisms, which may cause inter-individual variability with different concentrations of drugs. In addition, anticancer therapies are known to have a narrow therapeutic range; a high concentration in a patient’s body increases the toxicity, and a low concentration decreases the effect of the drug. Various combinations of cytotoxic chemotherapeutic drugs such as cyclophosphamide, anthracyclines, and taxanes are an integral part of the systemic treatment of breast cancer patients. Genetic variations such as single nucleotide polymorphisms (SNPs) are present across individuals and might affect pharmacokinetics and pharmacodynamics of drugs. In this review, we highlight obtained from recent studies on genetic variants associated to pharmacokinetics and pharmacodynamics of most of the important drugs used in neo-adjuvant chemotherapy of breast cancer like cyclophosphamide, doxorubicin, Epirubicin, paclitaxel, docetaxel and 5-fluorouracil.

کلیدواژه ها

breast cancer, genetic polymorphisms, neo-adjuvant chemotherapy, cyclophosphamide, doxorubicin, Epirubicin, paclitaxel

مقالات مرتبط جدید

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.